- Home
- IGMS vs PSNYW Comparison
IGMS vs PSNYW Comparison
Compare IGMS & PSNYW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- PSNYW
- Stock Information
- Founded
- IGMS 1993
- PSNYW N/A
- Country
- IGMS United States
- PSNYW Sweden
- Employees
- IGMS N/A
- PSNYW 2515
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- PSNYW Auto Manufacturing
- Sector
- IGMS Health Care
- PSNYW Consumer Discretionary
- Exchange
- IGMS Nasdaq
- PSNYW Nasdaq
- Market Cap
- IGMS 348.5M
- PSNYW 324.1M
- IPO Year
- IGMS 2019
- PSNYW N/A
- Fundamental
- Price
- IGMS $1.77
- PSNYW $0.23
- Analyst Decision
- IGMS Hold
- PSNYW
- Analyst Count
- IGMS 8
- PSNYW 0
- Target Price
- IGMS $6.14
- PSNYW N/A
- AVG Volume (30 Days)
- IGMS 779.9K
- PSNYW N/A
- Earning Date
- IGMS 03-06-2025
- PSNYW N/A
- Dividend Yield
- IGMS N/A
- PSNYW N/A
- EPS Growth
- IGMS N/A
- PSNYW N/A
- EPS
- IGMS N/A
- PSNYW N/A
- Revenue
- IGMS $2,918,000.00
- PSNYW N/A
- Revenue This Year
- IGMS $23.57
- PSNYW N/A
- Revenue Next Year
- IGMS $192.36
- PSNYW N/A
- P/E Ratio
- IGMS N/A
- PSNYW N/A
- Revenue Growth
- IGMS 57.64
- PSNYW N/A
- 52 Week Low
- IGMS $1.59
- PSNYW N/A
- 52 Week High
- IGMS $22.50
- PSNYW N/A
- Technical
- Relative Strength Index (RSI)
- IGMS 19.54
- PSNYW 60.29
- Support Level
- IGMS $1.59
- PSNYW $0.20
- Resistance Level
- IGMS $2.06
- PSNYW $0.24
- Average True Range (ATR)
- IGMS 0.45
- PSNYW 0.04
- MACD
- IGMS -0.30
- PSNYW 0.00
- Stochastic Oscillator
- IGMS 3.27
- PSNYW 34.75
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About PSNYW Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)
Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market-leading standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from USA.